Home > News > BioSante Pharmaceuticals Announces Results
August 16th, 2004
BioSante Pharmaceuticals Announces Results
BioSante reported a net loss of approximately $2.6 million (or $0.15 per share) for the quarter, compared to a net loss of approximately $1.6 million (or $0.18 per share) for the same period in 2003. The increased total net loss was due primarily to increased expenses related to development of the company's hormone therapy products, including the ongoing Phase III clinical trial of Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of menopausal symptoms.
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014
Aspen Aerogels, Inc. Schedules Second Quarter 2014 Earnings Release and Conference Call July 15th, 2014
Nanometrics to Announce Second Quarter Financial Results on July 30, 2014 July 9th, 2014
Small, but heading for the big time: Nanobiotix revenue for the 1st quarter of 2014 and new composition of the shareholding May 12th, 2014